News articles about BioMarin Pharmaceutical (NASDAQ:BMRN) have been trending somewhat positive recently, according to Accern. The research firm identifies positive and negative press coverage by monitoring more than twenty million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. BioMarin Pharmaceutical earned a media sentiment score of 0.10 on Accern’s scale. Accern also assigned media headlines about the biotechnology company an impact score of 47.4912508412406 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the near term.
These are some of the headlines that may have impacted Accern Sentiment Analysis’s scoring:
- Wedbush Reaffirms “Outperform” Rating for BioMarin Pharmaceutical (BMRN) (americanbankingnews.com)
- BRIEF-Biomarin Receives Anticipated Notification Of PDUFA Extension For Pegvaliase Biologics License Application (BMRN) (markets.businessinsider.com)
- BioMarin Receives Anticipated Notification of PDUFA Extension for Pegvaliase Biologics License Application (BLA) to May 28, 2018 (finance.yahoo.com)
- BioMarin's (BMRN) Gene Therapy Enters First Phase III Study (finance.yahoo.com)
- BioMarin’s (BMRN) Gene Therapy Enters First Phase III Study (zacks.com)
BioMarin Pharmaceutical (NASDAQ:BMRN) traded down $1.09 on Friday, reaching $90.46. 955,405 shares of the company’s stock were exchanged, compared to its average volume of 1,200,000. BioMarin Pharmaceutical has a 1 year low of $80.10 and a 1 year high of $100.51. The company has a debt-to-equity ratio of 0.41, a current ratio of 4.91 and a quick ratio of 3.81. The firm has a market capitalization of $15,890.00, a P/E ratio of -108.99 and a beta of 1.82.
BMRN has been the topic of several research analyst reports. Goldman Sachs Group restated a “buy” rating and issued a $129.00 price objective on shares of BioMarin Pharmaceutical in a research note on Friday, October 6th. Royal Bank of Canada initiated coverage on shares of BioMarin Pharmaceutical in a research note on Thursday, September 14th. They issued a “sector perform” rating and a $93.00 price objective on the stock. Wedbush restated a “neutral” rating and issued a $108.00 price objective on shares of BioMarin Pharmaceutical in a research note on Wednesday, November 15th. J P Morgan Chase & Co set a $131.00 price objective on shares of BioMarin Pharmaceutical and gave the stock a “buy” rating in a research note on Monday, November 27th. Finally, BidaskClub upgraded shares of BioMarin Pharmaceutical from a “strong sell” rating to a “sell” rating in a research note on Saturday, December 16th. Three equities research analysts have rated the stock with a sell rating, seven have given a hold rating, sixteen have assigned a buy rating and one has issued a strong buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and a consensus price target of $112.44.
In other BioMarin Pharmaceutical news, EVP Robert Baffi sold 18,415 shares of BioMarin Pharmaceutical stock in a transaction on Thursday, September 28th. The stock was sold at an average price of $92.43, for a total transaction of $1,702,098.45. Following the completion of the transaction, the executive vice president now directly owns 129,083 shares of the company’s stock, valued at $11,931,141.69. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Elaine J. Heron sold 800 shares of BioMarin Pharmaceutical stock in a transaction on Thursday, December 14th. The shares were sold at an average price of $88.90, for a total value of $71,120.00. Following the transaction, the director now directly owns 38,385 shares of the company’s stock, valued at $3,412,426.50. The disclosure for this sale can be found here. Over the last three months, insiders have sold 20,415 shares of company stock valued at $1,875,986. Company insiders own 1.85% of the company’s stock.
TRADEMARK VIOLATION WARNING: This piece was published by Community Financial News and is the sole property of of Community Financial News. If you are reading this piece on another publication, it was illegally copied and republished in violation of United States and international trademark & copyright laws. The legal version of this piece can be accessed at https://www.com-unik.info/2017/12/22/somewhat-favorable-press-coverage-somewhat-unlikely-to-impact-biomarin-pharmaceutical-bmrn-stock-price.html.
BioMarin Pharmaceutical Company Profile
BioMarin Pharmaceutical Inc is a biotechnology company. The Company develops and commercializes pharmaceuticals for various diseases and medical conditions. As of December 31, 2016, the Company’s therapy portfolio consisted of five products, and multiple clinical and pre-clinical product candidates. Its commercial products include Aldurazyme (laronidase) for Mucopolysaccharidosis I (MPS I), Firdapse (amifampridine phosphate) for Lambert Eaton Myasthenic Syndrome (LEMS), Kuvan (sapropterin dihydrochloride) for phenylketonuria (PKU), Naglazyme (galsulfase) for Mucopolysaccharidosis VI (MPS VI) and Vimizim (elosulfase alpha) for Mucopolysaccharidosis IV Type A (MPS IV A).
What are top analysts saying about BioMarin Pharmaceutical? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for BioMarin Pharmaceutical and related companies.